<DOC>
	<DOC>NCT00319254</DOC>
	<brief_summary>The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.</brief_summary>
	<brief_title>Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Stage IIIB, IIIC or IV breast cancer not curable with available therapy. Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens. Life expectancy of at least 16 weeks. Ability to swallow whole capsules. Use of or requirement for bisphosphonates within 8 weeks prior to screening. Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc. Recent or ongoing significant gastrointestinal disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>